(Q33836681)

29 July 2017

8 references

23 March 2019

1 August 2019

2 November 2019

20 November 2019

27 November 2019

26 October 2020

1 February 2021

28 October 2022

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy (English)

1 reference

mycobacterium infectious disease

29 July 2017

main subject

8 references

23 March 2019

1 August 2019

2 November 2019

20 November 2019

27 November 2019

26 October 2020

1 February 2021

28 October 2022

tumor necrosis factor

2 references

1 August 2019

1 February 2021

1 reference

2 November 2019

1 reference

20 November 2019

1 reference

27 November 2019

immunosuppressive drug

1 reference

26 October 2020

1

Kevin L Winthrop

1 reference

29 July 2017

Eric Chang

2

1 reference

29 July 2017

Shellie Yamashita

series ordinal

3

1 reference

29 July 2017

Michael F Iademarco

series ordinal

4

1 reference

29 July 2017

Philip A LoBue

series ordinal

5

1 reference

29 July 2017

publication date

1 October 2009

9 references

Emerging Infectious Diseases

29 July 2017

23 March 2019

1 August 2019

2 November 2019

20 November 2019

27 November 2019

26 October 2020

1 February 2021

28 October 2022

9 references

29 July 2017

23 March 2019

1 August 2019

2 November 2019

20 November 2019

27 November 2019

26 October 2020

1 February 2021

28 October 2022

15

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

1556-1561

1 reference

Mycobacterial disease in patients with rheumatic disease

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Tuberculosis associated with therapy against tumor necrosis factor alpha

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Defects in the interferon-gamma and interleukin-12 pathways

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Nontuberculous mycobacteria in the environment

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

The epidemiology of rheumatoid arthritis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2866401

Granulomatous infections due to tumor necrosis factor blockade: correction

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19861045

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nontuberuclous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19861045

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19861045

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3201/EID1510.090310

1 reference

29 July 2017

1 reference

29 July 2017

1 reference